Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 1—January 2005

Mycobacterium lentiflavum Infection in Immunocompetent Patient

Chiara Molteni*, Lidia Gazzola*, Miriam Cesari*, Alessandra Lombardi*, Franco Salerno*, Enrico Tortoli†, Luigi Codecasa‡, Valeria Penati‡, Fabio Franzetti*, and Andrea Gori*Comments to Author 
Author affiliations: *University of Milan, Milan, Italy; †Careggi Hospital, Florence, Italy; ‡Villa Marelli Institute, Milan, Italy

Main Article


Summary of clinical features for 14 patients with Mycobacterium lentiflavum infection*

Patient no.
(ref. no.) Age Sex Concomitant disease Intercurrent treatment Side of infection Susceptibility test Antimycobacterial therapy Clinical outcome
1 (3) 19 mo M No No Cervical lymph node No Surgical excision Recovery (resolved)
2 (4) 42 mo M No No Cervical lymph node No Surgical excision Recovery
3 (4) 33 mo M No No Cervical lymph node No Surgical excision Recovery
4 (2) 6 y F No No Cervical lymph node ND Rif, clm/3 wk
surgical excision Recovery
5 (2) 4 y F ND ND Cervical lymph node ND Inh, rif/†
surgical excision Recovery
6 (2) 4 y M ND ND Cervical lymph node ND surgical excision Recovery
7 (6) 3 y M No No Cervical lymph node ND Clm, eth/6mo Persistent suppuration
8 (I7) 52 y F Antisynthetase syndrome Corticosteroid Synovial fluid of wrist inh R, rif R, str R, eth R, pza R, cys S inh, rif, eth, pza/†
fus, levo, clm/1wk Exitus
9 (8) 49 y M HIV infection HAART Blood, lung clm S, rib S clm, rib, eth/4mo Recovery
10 (1) 85 y F Diabetes mellitus ND Thoracic vertebrae No inh, rif, pza/3mo
Inh, rif/6mo Improvement
11 (2) 58 y M Rheumatoid arthritis Corticosteroid Lung ND inh, rib, eth, pza/4mo No improvement
12 (2) 61 y F COPD, ovarian carcinoma Reiterated chemotherapy Lung ND rif, inh, pza/†
rib, eth, clm, cip/† No improvement (unchanged)
13 (2) 45 y M HIV infection, NHL HAART Hepatic nodular lesion ND rib, clm, eth, cip/2 mo
Rib, clm/4mo Recovery
14 (Molteni) 70 y F COPD, lung fibrodystrophy No Lung inh R, str R, rif R, amik R, km R, pza R, oflox R, clm S, eth S, cys S, ter S, rib S cip, inh/1mo
inh, pza, eth, rif/3mo
clm, eth, rib, cip/2wk No improvement

*M, male; F, female; ND, not done; COPD, chronic obstructive pulmonary disease; HAART, higly active antiretroviral therapy; amik, amikacin; clm, clarithromycin; cys, cycloserine; eth, ethambutol, fus, fusidic acid; inh, isoniazid; km, kanamycin; levo, levofloxacin; oflox, ofloxacin, pza, pyrazinamide; rib, rifabutin; rif, rifampin, str, streptomycin; ter, terizidon.
†Treatment duration not determined.

Main Article

  1. Springer  B, Wu  WK, Bodmer  T, Haase  G, Pfyffer  GE, Kroppenstedt  RM, Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol. 1996;34:11007.PubMedGoogle Scholar
  2. Tortoli  E, Piersimoni  C, Kirschner  P, Bartoloni  A, Burrini  C, Lacchini, et al. Characterization of mycobacteria isolates phylogenetically related to, but different from Mycobacterium simiae. J Clin Microbiol. 1997;35:697702.PubMedGoogle Scholar
  3. Cabria  F, Torres  MV, Garcia-Cia  JI, Dominguez-Garrido  MN, Esteban  J, Jimenez  MS. Cervical lymphadenitis caused by Mycobacterium lentiflavum. Pediatr Infect Dis. 2002;21:5745. DOIPubMedGoogle Scholar
  4. Haase  G, Kentrup  H, Skopnik  H, Springer  B, Böttger  C. Mycobacterium lentiflavum: an etiological agent of cervical lymphadenitis. Clin Infect Dis. 1997;25:12456. DOIPubMedGoogle Scholar
  5. Tortoli  E, Bartoloni  A, Erba  ML, Levre  E, Lombardi  N, Mantella  A, Human infections due to Mycobacterium lentiflavum. J Clin Microbiol. 2002;40:7289. DOIPubMedGoogle Scholar
  6. Uria  MJ, Garcia  J, Menendez  JJ, Jimenez  MS. Mycobacterium lentiflavum infection: case history and review of the medical literature. Enferm Infecc Microbiol Clin. 2003;21:2745.PubMedGoogle Scholar
  7. Ibanez  R, Serrano-Heranz  R, Jimenez-Palop  M, Roman  C, Corteguera  M, Jimenez  S. Disseminated infection caused by slow-growing Mycobacterium lentiflavum. Eur J Clin Microbiol Infect Dis. 2002;21:6912. DOIPubMedGoogle Scholar
  8. Niobe  SN, Bebear  CM, Clerc  M, Pellegrin  JL, Bebear  C, Maugein  J. Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol. 2001;39:20302. DOIPubMedGoogle Scholar
  9. Galarraga  MC, Torreblanca  A, Jimenez  MS. Isolation of Mycobacterium lentiflavum in a case of suspected lung cancer. Enferm Infecc Microbiol Clin. 2002;20:934.PubMedGoogle Scholar
  10. Migliori  GB, Centis  R, Fattorini  L, Besozzi  G, Saltini  C, Orefici  G, Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. Eur Respir J. 2003;21:12934. DOIPubMedGoogle Scholar

Main Article

Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.